This article highlights clinical and economic factors associated with Demodex blepharitis as well as diagnostic complexities, limitations of traditional therapies, the safety and efficacy of the 1 ...

Dealing with red, itchy eyelids? The culprit could be a common mite. This article is sponsored by XDEMVY. Dr. Watson is a ...

Tarsus Pharmaceuticals' lotilaner shows strong market performance for Demodex blepharitis, but cautious investment due to ...

While they are a normal part of the skin's microbiome, an overgrowth of these mites can lead to various skin and eye conditions, most notably Demodex blepharitis. This condition is characterized ...

An expert provides insights into the cost of misdiagnosed Demodex blepharitis and payer considerations for a potential cost-effective treatment. Eric D. Donnenfeld, MD; underscores the ...

Good news—most of these eyelash loss mistakes are easily fixed. Just like the hair on your head, it’s completely normal to ...

Cory Jubinville, PhD, an analyst from LifeSci Capital, maintained the Buy rating on Tarsus Pharmaceuticals (TARS – Research Report). The ...

Position Trading Today, the company sells one drug that could, potentially, treat 25 million people in the U.S. with Demodex blepharitis, a condition that occurs when mites build up in the eyelashes.

This follows a successful 2024 for Tarsus, highlighted by the strong launch of XDEMVY, a treatment for Demodex blepharitis, generating over $113 million in sales. Tarsus is also pursuing ...

Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as ...

Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as ...